Donald Darkin - ResMed Insider

RMD -- USA Stock  

USD 108.52  0.81  0.74%

Mr. Don Darkin is President innovation operations of Resmed Inc. Previously, Mr. Darkin was president, sleepdisordered breathing strategic business unit, a position he began in May 2011, and senior vice president, strategic business unit patient interfaces from July 2007 to May 2011. Before these positions, Mr. Darkin held several senior roles within ResMed. He joined ResMed in August 1999 as vice president, product development. In May 2005, he became director of operations in France for ventilation, and subsequently served as vice president, business divisions, and senior vice president, global product development. Before working at ResMed, Mr. Darkin served as vice president of operations for Ambri Pty Ltd., Australia, and vice president, product development for Telectronics Medical Systems Australia and US. Mr. Darkin is identified as an inventor or coinventor on over 80 granted patents worldwide. Mr. Darkin was educated in the UK in mechanical engineering and has further professional management training from University of New South Wales and Massachusetts Institute of Technology.
Age: 61  President Since 2014      

Management Efficiency

The company has Return on Asset of 9.58 % which means that on every $100 spent on asset it made $9.58 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.68 % implying that it generated $15.68 on every 100 dollars invested.
The company has 810 M in debt with debt to equity (D/E) ratio of 39.1 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed has Current Ratio of 3.41 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Clare TrachtmanBaxter International
Byron SelmanHaemonetics Corporation
Paul VibertBaxter International
Charles BodnerBecton Dickinson and Company
Carlos AlonsoHill Rom Holdings
Albert WhiteThe Cooper Companies
Carlos MarumHill Rom Holdings
James LimBecton Dickinson and Company
Thomas McCurdyHaemonetics Corporation
Deborah RasinHill Rom Holdings
Richard WagnerHill Rom Holdings
Eric NodiffCantel Medical Corp
Alexandre ConroyBecton Dickinson and Company
Stephen SichakBecton Dickinson and Company
Thomas PolenBecton Dickinson and Company
David HelselHaemonetics Corporation
Todd AbrahamEndologix
Neil RydingHaemonetics Corporation
Michael MurphyHill Rom Holdings
Sean MartinBaxter International
Dottie DonnellyBrienzaCantel Medical Corp

Entity Summary

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and traded on BATS Exchange. It employs 6000 people.ResMed (RMD) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 6,000 people. ResMed is listed under Medical Equipment category by Fama And French industry classification.

ResMed Leadership Team

John Wareham, Independent Director
Ronald Taylor, Lead Independent Director
Rob Douglas, President COO
Christopher Roberts, Independent Director
Gary Pace, Independent Director
Chris Roberts, Independent Director
Robert Douglas, Pres and COO
Agnes Lee, Senior Director - Investor Relations
Carol Burt, Independent Director
Rich Sulpizio, Independent Director
Peter Farrell, Non-Executive Chairman of the Board
Jim Hollingshead, President - Americas
Brett Sandercock, CFO and Principal Accounting Officer
Ron Taylor, Lead Independent Director
Don Darkin, President - Sleep-disordered Breathing Strategic Business Unit
Jack Wareham, Independent Director
Anne Reiser, President Europe
Karen Drexler, Director
Raj Sodhi, President ? Software as a Service (SaaS) Business and CTO
David Pendarvis, Chief Admin. Officer, Global General Counsel and Secretary
Richard Sulpizio, Independent Director
Michael Farrell, CEO and Director
Richard McHale, President ? Respiratory Care
Donald Darkin, President ? innovation & operations

Stock Performance Indicators

Current Sentiment - RMD

ResMed Investor Sentiment
Greater number of Macroaxis users are at this time bullish on ResMed. What is your perspective on investing in ResMed? Are you bullish or bearish?
98% Bullish
2% Bearish
Currently Active Assets on Macroaxis
Purchased over 20 shares of
few hours ago
Traded for 106.27
Purchased over 200 shares of
few hours ago
Traded for 10.56
Purchased over 70 shares of
few hours ago
Traded for 39.4
Purchased few shares of
few hours ago
Traded for 1184.91
Purchased over 40 shares of
few hours ago
Traded for 69.22
Additionally take a look at Your Equity Center. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.